What You Should Know:
-Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX) to use human genetics and machine learning to improve the discovery and development of new precision medicines.
-The partnership, which began in 2018, was previously extended in 2021. The collaboration will now run until 2026.
Vertex and
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine
What You Should Know:
- Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.
- Powered by NVIDIA HGX H100 systems and running on Dell
Read More
Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery
What You Should Know:
- Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies.
- These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas.
Unveiling the Power of Clinico-Genomic Data
The datasets offer a unique combination of longitudinal
Read More
Weave Bio Launches for AI-Powered Drug Development, Secures $10M
What You Should Know:
- Weave Bio, an AI-native life sciences platform company, announced today the public release of its flagship offering, AutoIND, and $10 million in seed funding co-led by Innovation Endeavors and Magnetic Ventures.
- AutoIND marks a significant advancement in drug development by automating and accelerating the preparation, writing, and review process for Investigational New Drug (IND) applications.
Automating the IND Process: A Game-Changer for Drug
Read More
Sanofi, Formation Bio, OpenAI Partner on AI-Powered Drug Discovery
What You Should Know:
- Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.
- Sanofi, Formation Bio, and OpenAI believe this collaboration will be
Read More
Accenture Backs Turbine’s AI-Powered Platform to Accelerate Drug Discovery
What You Should Know:
- Accenture Ventures, the venture capital arm of Accenture, has announced a strategic investment in Turbine, a company pioneering the use of predictive cell simulations for drug development.
- The investment aims to empower Turbine in extending its innovative technology to global biopharmaceutical companies seeking to unlock hidden biological insights and accelerate crucial drug development processes.
Optimizing Drug Discovery with Simulated
Read More
Every Cure and BioPhy Partner to Repurpose Existing Drugs Faster with AI
What You Should Know:
- BioPhy, an AI drug development company, and Every Cure, a non-profit dedicated to unlocking the potential of existing drugs for new uses, today announced a strategic partnership to revolutionize drug repurposing through artificial intelligence (AI).
- The partnership follows Every Cure's recent funding from the Advanced Research Projects Agency for Health (ARPA-H). A successful pilot using AI led to the identification of potential treatments for diseases like sickle
Read More
Deciphex & Novartis Partner on AI-Powered Pathology for Drug Discovery
What You Should Know:
- Deciphex, a leading digital pathology company based in Dublin, Ireland, has announced a collaborative effort with Novartis, a prominent multinational pharmaceutical corporation.
- The strategic partnership focuses on developing innovative artificial intelligence (AI) solutions aimed at revolutionizing preclinical pathology assessments within the drug discovery and development process.
Optimizing Preclinical Pathology with AI
The collaboration
Read More
NVIDIA Healthcare Launches Generative AI Microservices for Drug Discovery
What You Should Know:
NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest advances in generative AI from anywhere and on any cloud.The new suite of NVIDIA healthcare microservices includes optimized NVIDIA NIM AI models and workflows with industry-standard APIs, or application programming interfaces, to serve as building blocks for creating and deploying cloud-native applications. They offer advanced
Read More
Absci Announces $75M Public Offering to Fuel AI Drug Creation
What You Should Know:
- Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock.
- This IPO aims to support the advancement of Absci's internal drug development programs, further investment in their Integrated Drug Creation™ platform, and general corporate purposes.
Offering Details
Absci intends to offer $75M of common stock, with an option to sell an additional $11.25M
Read More
